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Abstract    
Consumption of cocoa-enriched dark chocolate (DC) has been shown to alter glucose and 
insulin concentration during rest and exercise compared to an iso-caloric/carbohydrate 
(CHO) cocoa-depleted control (CON). However, the impact of DC consumption on exercise 
metabolism and performance is uncertain.  Therefore the current aim was to investigate CHO 
metabolism via stable isotope tracer techniques during exercise after subjects ingested either 
DC or CON.  Sixteen overnight-fasted male cyclists (30 ± 6 yrs; 72.8 ± 6.0 kg, 56.3 ± 5.7  
ml/kg/min VO2max) performed two trials in a single blinded, randomized, cross-over design,  
after consuming either DC (561 kcal; 33.3 g CHO; 11.4 g cocoa) or CON (544 kcal; 27.5 g 
CHO; <0.5 g cocoa) 2 h prior to 2.5 h of steady-state (SS) exercise (~45% VO2peak).  This 
was followed by a ~15 min time-trial (TT) and 60 min of recovery. [6,6-2H2]Glucose and [U-
13C]glucose were continuously infused during SS to assess glucose rate of appearance (Ra) 
and disappearance (Rd).  After DC consumption, plasma (-)-epicatechin, theobromine, 
glucose and insulin concentrations were significantly (p<0.001) elevated throughout vs. CON.  
During SS, there was no difference in [6,6-2H2]glucose Ra between treatments, but towards 
the end of SS (last 60 min) there was a ~16% decrease in Rd in DC vs. CON (p<0.05). 
Accordingly, after DC there was a ~18% significant decrease in plasma glucose oxidation 
(trial effect; p=0.032), and a ~15% increase in tracer derived muscle glycogen utilization 
(p=0.045) late during SS exercise.  This was without effect on TT performance. The higher 
blood glucose concentrations during exercise and recovery after DC consumption coincided 
with high concentrations of polyphenol and/or methylxanthine compounds but not caffeine.  
In summary, DC consumption altered muscle CHO partitioning, between muscle glucose 
uptake and glycogen oxidation, but this was without any effect on cycling TT performance.    
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Introduction  
As early as 1552, chocolate and/or cocoa have been consumed as a medicinal and cultural 
treatment for fatigue in Mexican Mayan and Aztec cultures (Dillinger et al. 2000).  However, 
very few studies have examined metabolic and anti-fatigue effects of dark chocolate. Recent 
studies have shown that 100 g of dark chocolate increased the concentration of plasma 
glucose (Davison et al. 2011), and chronic dark chocolate consumption caused a ~21% 
increase in plasma free-fatty acids (Allgrove et al. 2011), during prolonged exercise 
compared to a iso-fat/calorie/carbohydrate (CHO) control.  But, these studies did not 
examine mechanisms associated with these shifts in metabolism during exercise, nor 
performance outcomes.   
Beyond CHO and lipids, dark chocolate also contains cocoa derived phytochemicals, among 
which are many potentially bioactive compounds (Bruinsma et al. 1999).  These compounds 
intrinsic to cocoa include the methylxanthines such as theobromine and caffeine, as well as 
polyphenols, of which (-)-epicatechin is the most abundant (Schroeter et al. 2006).  
Methylxanthines (primarily caffeine) have consistently been shown to increase exercise 
capacity and performance (Burke 2008; Graham et al. 2008)).  However, the effects of 
methylxanthines (mainly caffeine) on glucose disposal (glucose uptake, rate of 
disappearance (Rd) or glucose oxidation) have been inconsistent. Most studies showed a 
decrease (Graham, Battram et al. 2008), while others showed no change (Roy et al. 2001; 
Hulston et al. 2008) or increase in glucose oxidation during exercise (Yeo et al. 2005).  
Another methylxanthine (theophylline) has also shown a significant decrease in glucose Rd 
during exercise (Raguso et al. 1996). These results suggest that component(s) within dark 
chocolate could have a potential impact on fatigue and performance. 
The causes of fatigue and limits to performance during prolonged endurance exercise are 
multi-factorial in nature.  However, one mechanism for prolonged exercise performance 
appears to be the maintenance of blood glucose levels (for review see: (Jeukendrup 2004)).  
The importance of euglycemic blood glucose concentrations for enhanced performance 
during prolonged exercise, together with the recent findings of a better maintenance of 
plasma glucose with dark chocolate consumption during prolonged exercise (Davison, 
Callister et al. 2011), which could provide substrate to maintain carbohydrate oxidation, 
provided the rationale for the current study.  Our primary aim was to characterize glucose 
turnover using continuous [6,6-2H2]glucose and [U-
13C]glucose dual-tracer infusion with 
breath and blood measurements to demonstrate the mechanisms by which cocoa-rich dark 
chocolate consumption results in associated increases in blood glucose during steady-state 
exercise and recovery.  Accordingly, we assessed glucose rate of appearance, 
disappearance, oxidation and determined indirect measurements of gluconeogenesis and 
glycogen utilization throughout the entire steady-state exercise period.  Secondly, we 
incorporated a cycling time-trial to ascertain whether a potentially enhanced maintenance of 
blood glucose after DC consumption would be associated with greater exercise performance.  
  
Materials and Methods 
Volunteers  
Sixteen healthy male cyclists (4-20 h/ week of training) participated in this study and are 
characterized in Table 1. Volunteers were excluded if having a nut allergy, smokers or on 
regular medication and were informed verbally and in writing about the nature and potential 
risks of the experimental procedures before written informed consent was obtained.  The 
study was approved by the ethics committee of the University of Lausanne, Switzerland. The 
clinical trial was conducted following the principles of International Conference on 
Harmonization guideline for Good Clinical Practice (GCP).  This study was conducted from 
March 2008 until January 2010.    
 
General study design and treatment composition 
After pre-experimental testing, each volunteer performed two trials separated by at least one 
week in a single blinded, randomized, cross-over design.  In each trial, volunteers either 
consumed 561 kcal of dark chocolate (DC; Nestlé Noir Intense- 70% Cocoa) or closely 
matched CHO, fat and calorie control chocolate (CON; Table 2) 2 h prior to exercise.  
Volunteers then cycled for 2.5 h at ~45% VO2peak in steady-state conditions (SS), followed by 
a ~15 min time-trial (TT; Fig. 1).  Recovery measurements were then made as subjects 
rested over another 60 min (RECOV).  To characterize whole-body and glucose metabolism, 
frequent breath and blood (n=17) measurements were made and [6,6-2H2]glucose and [U-
13C]glucose tracers were infused prior to SS and TT cycling, as well as during RECOV.   
 
Pre-experimental trial testing 
At least 10 days prior to the first experimental trial, volunteers performed a continuous 
incremental cycling test on a cycle ergometer (Excalibur-Lode, Groningen, The Netherlands) 
to exhaustion to determine peak oxygen uptake (VO2peak; VMax 29C, SensorMedics, 
Bilthoven, The Netherlands) and maximal workload capacity (Wmax; Table 1).  On the first 
visit, the cycle ergometer was individually adjusted for each subject and was set accordingly 
for all subsequent tests. Heart rate (HR) was monitored every 5 sec by near infrared 
telemetry (Polar NV, Polar Electro, Kempele, Finland).  The VO2peak test started at 100W for 
5min, followed by 50W increases every 2.5 min until HR>160 beats/min.  Subjects then 
increased 25W every 2.5 min until exhaustion (RQ>1.1; HR max; plateau and/or exhaustion).  
Wmax was then calculated as Wmax = Wout + (t/150) * 25, where Wout equaled the last workload 
(wattage attained), and t was the time (sec) at the last workload (Jeukendrup et al. 1996).   
 
At least 7 days prior to the first experimental session, the subjects underwent a full 
familiarization trial for the 2.5h exercise protocol, which confirmed the power output of ~45% 
VO2peak required for each subject and TT familiarization. Previous investigations have shown 
that serial TTs, without distance or time feedback, result in progressively improved 
performances, being nearly optimal by the second or third blinded TT (Mauger et al. 2009). 
Thus, a practice familiarization TT was implemented to ensure that subjects had learned the 
best possible pacing strategy prior to the experimental trials so that any differences would be 
due to the experimental conditions. 
 
Activity and diet prior to experimental trials 
All subjects were instructed to maintain their usual physical activity patterns throughout the 
experimental period.  However, for the 48 h prior to all pre-testing and experimental trials 
subjects abstained from any heavy exercise.  Starting one week prior to the two experimental 
trials, subjects were placed on dietary restrictions including no alcohol, corn starch, colas or 
high caffeine/ polyphenol containing foods or beverages. Dietary instructions and food lists 
restricted products with a high natural abundance of 13C-carbohydrates (e.g. C4 plants such 
as maize or sugar cane) to reduce 13C background shift from endogenous substrate stores to 
allow for better accuracy of the [U-13C]glucose tracer.  Volunteers were instructed to 
document all food intake and exercise for the 48 h prior to the first full experimental trial, and 
this diet was then duplicated prior to the second experimental session, of which 100% 
compliance was reported.  Only water was allowed from 9 pm the night before each trial.   
 
Experimental trials  
Figure 1 provides a schematic drawing of the entire experimental protocol.  Volunteers 
arrived overnight fasted at 8:00am, weighed, and completed a 24 h food/ beverage 
questionnaire to confirm compliance to the dietary controls. Teflon catheters (B/BRAUN 18 
gauge, Melsungen A.G.) were then inserted into each antecubital vein for blood sample 
drawing and for subsequent infusion of labeled glucose at the beginning of exercise (see 
Tracer infusion section below for full details).  Thereafter, the first resting blood sample was 
taken and expired breath sample was collected into a vacutainer tube.  The subject then 
received the randomized treatment of either DC or CON to consume within a 10min period.  
Although the researchers and subjects were blinded to the identity of the treatment, the 
treatments were not visually identical.  Upon completion of the treatment, another blood and 
breath sample was taken (time point = 0min), and additional resting state blood and breath 
samples were taken at 15, 30, 45, 60, 90 and 120min after the time 0.  The tracer infusion 
was started at 90min after the treatment, which was 30min prior to the commencement of 
exercise with bolus prime, followed by a 4.5 h continuous infusion of [6,6-2H2]glucose and [U-
13C]glucose throughout exercise (SS and TT) and the recovery period.  During the 2.5 h SS 
cycling segment the power output on the cycle ergometer was manually set to 142.0±15.9 W 
to elicit 43.5±4.5% VO2peak so that the relative fuel utilization and metabolism of each subject 
could be assessed.  Within 5 min after the completion of the 2.5 h SS portion of the protocol 
the cycling ergometer was switched from manual to linear mode so the subject controlled 
power output by varying the pedal cadence for the TT according to the formula W = L x 
(RPM)2. The L (linear alpha factor) was based on the individual subjects Wmax and preferred 
cycling cadence during the VO2peak test. As described previously (Jeukendrup, Saris et al. 
1996), the individual amount of work (kJ) to complete was based on the individual subjects 
90% Wmax, with a required TT duration of ~10-12min, according to the formula: 
Required amount of work (kJ) = (0.90 x Wmax (W) x 600 (sec)) / 1000 
 
The aim of the TT test was for subjects to complete a set amount of work (203±15 kJ) as 
quickly as possible.  During the TT the only information the subject was given was the 
amount of work done and left to complete by a moving bar graph on a screen in front of him. 
No other objective external cues were available and no encouragement was given. One 
volunteer could not finish one of the TT’s, and his data have been omitted.  Immediately after 
the TT, recovery measurements were then made as subjects rested over another 60 min 
(RECOV).  Continuous blood and breath samples (n=17) were taken every 15-20 min 
throughout the entire SS, TT and RECOV periods (see Fig 1; Blood and breath analysis 
below).   
 
Tracer infusion  
Initially, volunteers received a 5 mL intravenous bolus prime of NaH13CO3 (165.04 µmol/mL; 
Eurisotope, France), [6,6-2H2]glucose (421 µmol/mL) and [U-
13C]glucose (57.7 µmol/mL) 
within 2 min.  Thereafter, a continuous infusion of sterile pyrogen free dual-labeled tracer 
solution containing [6,6-2H2]glucose and [U-
13C]glucose was delivered via a calibrated 
ARGUS 707V pump (Codan Medical AG, Baar, Switzerland) at the rates of 2.240±0.168 and 
0.032±0.002 µmol/kg/min, respectively.  Measured glucose concentrations in the infusates 
averaged 35.15 and 4.78 µmol/ml for the [6,6-2H2]glucose and [U-
13C]glucose, respectively.   
 
Blood and breath analysis  
Fourteen blood samples of 12 mL each (taken at -10, 15, 30, 45, 60, and then 90, 120, 140, 
160, 180, 210, 240, 300 and 360 min) and 3 drawings of 7 mL (taken at 0, 270 and 330 min) 
went to immediate separation for plasma. Then, aliquots of 0.5 mL were taken and stored. 
One aliquot was acidified for polyphenol analysis. Additionally, ten breath samples were 
taken at 120, 140, 160, 180, 210, 240, 270, 300, 330 and 360 min. 
 
Breath samples were analyzed for 13C/12C ratio by gas chromatography continuous flow 
isotope ratio mass spectrometer (GC-IRMS, Thermo Fischer, Bremen, Germany). The 
reference gas used was normalized with calibration gases of known isotopic ratio 
(Eurisotope, France).  
 
Isotopic enrichment of deuterated plasma glucose was measured by gas chromatography-
mass spectrometry (GC-MS) (Agilent, Santa Clara, USA). The analysis of the glucose penta-
acetate derivative was performed using chemical ionization mode with methane gas with 
selective monitoring at mass-to-charge ratios (m/z) 331 and 333. Briefly, 100 µL of plasma 
was deproteinized using 0.3 N barium hydroxide and 0.3 N zinc sulphate. After 
centrifugation, the supernatant was purified on ion exchange resins (AG50W-X8 and AG 1-
X8). To determine deuterated glucose isotopic enrichment (tracer over tracee ratio (TTR)) by 
GC-MS, half of the supernatant was dried under nitrogen gas and derivatized with a freshly 
prepared solution of acetic anhydride/pyridine (Wolfe et al. 2005). The remainder of the 
supernatant was diluted with water and filtered with a 0.2 µm filter (Waters, New Milford, MA, 
USA) and directly injected into an LC-IRMS to measure 13C/12C isotopic enrichment of 
plasma glucose (Godin et al. 2011). 
  
Aliquots of plasma samples were used for glucose, insulin, glucagon, triglyceride (TG), free-
fatty acid (FFA), noradrenaline, adrenaline, flavanols and methylxanthines quantification. 
Glucose and TG were assessed enzymatically by a Siemens Dimension clinical chemistry 
system (Siemens Healthcare Diagnostics Inc, Newark, USA), with D40 Dimension and 
DF69A Dimension clinical chemistry kits for glucose and TG, respectively. Glucagon and 
insulin were quantified by an immunoassay ELISA test kit (Roche Diagnostics, Germany) 
and RIA test kit (Euro-Diagnostica, Sweden), respectively. FFA was determined via an 
enzymatic colorimetric method assay (Wako Chemicals, GmbH).  Noradrenaline, adrenaline, 
flavanols and methylxanthines (theobromine and caffeine) were assessed by reverse phase 
HPLC using previously published methods (Georgia et al. 2001; Westermann et al. 2002; 
Ritter et al. 2010). 
 
Calculations  
VO2 and VCO2 were recorded on a breath by breath basis over a 5 to 8 min period prior to 
sampling time, and from these respiratory measures, total fat and carbohydrate oxidation 
rates were calculated using the non-protein respiratory quotient (Peronnet et al. 1991). 
  Fat oxidation rate = 1.695 VO2 – 3.22 VCO2    (Eq.1) 
 Carbohydrate oxidation rate = 4.585 VCO2 – 3.22 VO2   (Eq.2) 
 
VO2 and VCO2 are reported in liters per minute (L/min) and oxidation rates in grams/minute 
(g/min).   
 
The 13C/12C isotopic ratio is expressed as δ13C values calibrated against an international 
standard (Vienna Pee Dee Belemnite, VPDB; (Slater et al. 2001)).  The delta notation is 
defined as δ13C/12Csample, ‰ = (Rs / Rst - 1) × 1000, where Rs is the ratio of 
13C/12C in the 
sample and Rst is the ratio of ratio of the international standard used.  
The δ 13C/12C value was transformed into TTR according to equation 3. 
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Where Ristd is 0.011237, δsample and δblank are δ
 13C/12C of sample after infusion of tracer and 
δ13C of sample (at natural abundance) before the infusion of the tracer, respectively. ‘A’ is 
the skew factor (equivalent to “1-Ristd”) and “n” is the total number of labeled atoms (n=6, for 
[U-13C]glucose). 
 
The total glucose rate of appearance of glucose (Ra, Eq. 4), rate of disappearance of glucose 
(Rd, Eq. 5), glucose clearance rate (Eq. 6), gluconeogenesis (GNG; or glucose carbon 
recycling, Eq. 7), plasma glucose oxidation (Eq.8), fat and total glucose oxidation and muscle 
glycogen oxidation (Eq. 9) were calculated using the single pool non steady state model of 
Steele (Wolfe and Chinkes 2005) and as described by Jeukendrup et al. (Jeukendrup et al. 
1999). 
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Glucose clearance rate = Rd / ((C2 + C1)/2)     (Eq. 6) 
Where F is the infusion rate (µmol/kg/min), V is the volume of distribution (160 mL/kg), C2 
and C1 are the glucose concentrations at consecutive time points (e.g. t2 and t1) and E2 and 
E1 are the plasma glucose enrichments at consecutive time points (e.g. t2 and t1). 
 
GNG = Ra ([6,6-
2H2]glucose) – Ra ([U-
13C]glucose)     (Eq. 7) 
 
Plasma glucose and muscle glycogen oxidation (µmol/kg/min) were calculated according to 
the following equations (Jeukendrup, Wagenmakers et al. 1999):   
Plasma glucose oxidation = (Rd glucose) x (%glucose tracer oxidized)   (Eq. 8) 
 
Where % infused tracer oxidized was calculated as (V13CO2 x k
-1) / (infusion rate of [U-
13C]glucose) x 100, with k at 0.747. V13CO2 (µmol/kg/min) was calculated as ∆
13CO2 (isotopic 
enrichment of breath CO2 at a given time corrected by CO2 at natural abundance as 
background without any tracer) multiplied by VCO2.  
 
Muscle glycogen oxidation = Total CHO oxidation – plasma glucose oxidation  (Eq. 9) 
 
Statistics 
A mixed-model repeated measurement analysis was performed with F-tests on the time-
treatment interactions.  A mixed model allowed for correcting for time period residuals as well 
as any missing data points.  When data was not normally distributed, log-transformation was 
performed, and if still not normally distributed non-parametric tests were applied. Treatment 
differences at each time point were calculated according to Hodges-Lehmann and a 
Wilcoxon sign-rank test was performed. The area-under-the-curve (AUC) for the different 
outcomes was calculated using Kinetica software (Thermo Fisher Scientific Inc., MA, USA) 
and analyzed via paired t-tests. The statistical analysis was performed with SAS 9.1. (SAS 
Institute, Cary, NC, USA). All data are reported as mean ± standard error measurement 
(SEM).  
Results 
Plasma metabolite, hormone, (-)-epicatechin and theobromine concentrations 
Plasma glucose, insulin, glucagon and triglycerides are shown in figure 2. Time and 
treatment interaction was observed (p<0.0001), indicating that blood glucose post DC 
treatment was greater than CON (Fig. 2A). The glucose area under the curve (gAUC) was 
significantly greater during the SS, TT and RECOV periods after consuming DC vs. CON 
(Fig. 2B). Accordingly, over the entire measurement period, DC had a 5% greater gAUC 
compared to CON (p=0.0045). DC led to higher insulin levels during the pre-exercise rest 
than CON (Fig 2C).  The greatest differences between DC and CON insulin concentrations 
were observed during the later stages of the SS period. Insulin calculated AUC was higher 
(p<0.005) after DC compared to CON during the RECOV period (Fig. 2D).  Conversely, 
plasma glucagon was lower after DC compared to CON (p<0.0001; Fig. 2E), with the 
greatest difference between treatments at the end of the SS phase (Fig. 2F). Despite the 
similar fat content in the chocolate samples (42.7 and 47.6g for DC and CON, respectively) a 
significantly greater amount of TG over time was demonstrated with DC compared to CON 
(Fig. 2G, p<0.0001), with significantly higher TG values for DC vs. CON from 90 to 180 min 
after consumption (end of the resting and commencement of SS cycling phase).  However, 
there were no differences found between treatments for plasma FFA throughout rest, SS, TT 
or recovery time periods (data not shown).  At rest, plasma FFA was 140±40 μmol/L for both 
treatments.  Exercise caused a 5-fold increase in FFA, with peak values found at the end of 
the SS exercise period (790±101 μmol/L).  Plasma adrenaline and noradrenaline values 
were also assessed during the entire study. Adrenaline values did not show any difference 
between treatments (p=0.98).  Conversely, noradrenaline plasma levels showed a small, but 
significant, elevation in the CON trial vs. DC at the end of the time trial (P<0.01; data not 
shown).  Plasma theobromine, caffeine, and (-)-epicatechin metabolites were analyzed (Fig. 
3). Only data from the DC treatment are plotted, as the CON chocolate contained only trace 
levels of theobromine and flavanols (Table 2). After DC consumption, plasma theobromine 
concentrations peaked at 180 min, and by the start of the TT phase theobromine 
concentration was still within ~90% of the peak value, whereas plasma caffeine 
concentrations remained nearly at the baseline level (Fig. 3A).  Plasma concentrations of (-)-
epicatechin metabolites also peaked at 190 min (Fig. 3B).  By the start of the TT phase, all 
flavanol metabolites had appreciably decreased to ~65% of peak concentrations, declining 
further during RECOV.   
 
Plasma tracer kinetics in the SS phase 
The trial effect of DC on glucose rate of appearance (Ra) was not different between 
treatments whether measured via [6,6-2H2]glucose (p=0.263) or [U-
13C]glucose (Table 3), but 
the calculated glucose rate of disappearance (Rd) values for DC showed a ~16% reduction 
late during SS exercise (last 60 min) compared to CON with both [6,6-2H2]glucose and [U-
13C]glucose tracers (p<0.05; Table 3). Accordingly, calculated plasma glucose oxidation was 
significantly reduced by ~18% during last 60min of SS after DC compared to CON (trial 
effect; p=0.032; Table 3 & Fig. 4A), with a time and treatment interaction at 240 min 
(p=0.013). This was also reflected by significantly reduced calculated glucose clearance rate 
in the last hour of SS exercise (p<0.05; Figure 4C).   However, there was no significant 
difference in [6,6-2H2]glucose Ra-Rd AUC during SS exercise between treatments (p=0.71).  
There was a compensatory ~15% increase in calculated muscle glycogen oxidation after DC 
consumption versus CON (trial effect p=0.045; Fig. 4B). The difference between the glucose 
Ra between the two tracers ([6,6-
2H2]glucose and [U-
13C]glucose) can assess the glucose 
recycling rate and can be used as an indirect estimation of gluconeogensis (Jeukendrup, 
Wagenmakers et al. 1999). The values obtained for Ra via [6,6-
2H2]glucose and [U
13-
C]glucose were not significantly different (Table 3), thus glucose recycling, or estimated 
gluconeogensis, during the SS portion of exercise was minimal (p=0.72).    
 
Cardio-respiratory measures and substrate source utilization  
Regardless of the treatment, there were significant and similar increases in VO2, VCO2, 
ventilation (VE), heart rate (HR) and ratings of perceived exertion (RPE) from rest to SS 
exercise, and again from SS to TT.  The average values of VO2 for the SS phase were 
24.7±0.6 ml/Kg/min (44±4% of VO2peak) and 24.3±0.6 ml/Kg/min (43±5% of VO2peak) for DC 
and CON, respectively.  Throughout the SS exercise period, there was a progressive 
decrease in the respiratory exchange ratio (RER), as highlighted by increases in fat oxidation 
and corresponding decreases in carbohydrate oxidation (Supp. Table 1).   
 
Cycling Time-Trial Performance and recovery period 
There was no difference (p=0.39) in TT performance between treatments (11.5 ± 1.6 min vs. 
11.6 ± 1.1 for DC and CON, respectively). Seven volunteers showed a better TT 
performance after DC consumption, while seven performed better after CON, and one 
subject showed no difference between treatments.  In the recovery period, blood glucose and 
plasma insulin were significantly higher in the DC than in CON treatment (p<0.05; Fig 
2A,B,C&D). DC treatment also resulted in lower plasma concentrations of glucagon vs. CON 
in the early phase of recovery post TT, with the difference becoming insignificant by the end 
of recovery.  
  
Discussion 
To our knowledge this is the first study to characterize the altered whole-body glucose 
metabolism associated with cocoa-rich dark chocolate (DC) consumption using stable 
isotope methodologies during steady-state (SS) cycling exercise. These results demonstrate 
that the consumption of DC augments blood glucose concentrations during low-intensity 
exercise compared to a nearly iso-caloric and iso-carbohydrate cocoa-deplete control 
treatment (CON). The increased plasma glucose coincided with high concentrations of 
polyphenol and methylxanthine (primarily theobromine, but not caffeine) compounds found in 
DC that could potentially attenuate plasma glucose uptake.  However, this augmented 
plasma glucose concentrations with DC treatment did not impact upon cycling time-trial 
performance.  
 
The primary aim of this study was to clarify potential mechanism(s) associated with 
augmented glucose after DC consumption as found previously (Davison, Callister et al. 
2011). We also demonstrated a significant ~8% increase in blood glucose during the SS and 
TT phases of the protocol (Fig 2A&B) after DC consumption compared to CON despite the 
lower SS exercise intensity in the present study (~45% VO2peak vs. ~60% VO2peak (Davison, 
Callister et al. 2011)).  To gain insight into the physiological mechanism(s) behind these 
altered blood glucose responses the present study incorporated continuous [6,6-2H2]glucose 
and [U-13C]glucose tracers to ascertain glucose kinetics (rate of appearance, Ra; rate of 
disappearance, Rd) and to estimate rates of glucose clearance and gluconeogensis 
(Jeukendrup, Wagenmakers et al. 1999; Wolfe and Chinkes 2005).  There are two possible 
mechanisms that are potentially responsible for the increased plasma glucose during the SS 
phase: 1) an increase in the glucose Ra via exogenous (oral consumption) and/or 
endogenous (increased gluconeogenesis) carbohydrate provision and 2) a decrease in 
glucose Rd into primarily exercising skeletal muscle and, to a lesser extent, liver and other 
organs.  The current data demonstrated no change in Ra between treatments (p=0.261; 
Table 3).  Notwithstanding the technical constraints in perfect iso-caloric and carbohydrate 
matching between treatments (27 vs. 33g CHO in DC and CON, respectively), it is highly 
unlikely that the extra 6g of CHO provision from the DC treatment on glucose Ra would cause 
any impact during the 2h pre-exercise resting period, which is supported by near identical 
glucose concentrations postprandially (Fig 2A).  To examine the role of endogenous glucose 
production in glucose Ra, we included two glucose tracers ([U-
13C] vs. [6,6-2H2]glucose) in 
the study. Similar to Jeukendrup et al. (Jeukendrup, Wagenmakers et al. 1999), the current 
study showed that the calculated Ra were similar regardless of the glucose tracer used ([U-
13C] vs. [6,6-2H2]glucose), and that during steady state conditions ~90-100% of the glucose 
disposal was through oxidation (Table 3).  Under these conditions the glucose recycling rate 
was minimal; suggesting that glucose Ra via endogenous glucose output (liver derived 
gluconeogenesis) was negligible. However, tracers have considerable measurement 
variability that may have masked any small physiological differences in gluconeogenesis.  
Nevertheless, Cordero-Herrera et al. recently demonstrated that a cocoa phenolic extract or 
(-)-epicatechin directly suppressed glucose production in HepG2 liver cells (Cordero-Herrera 
et al. 2013).  Thus, further studies examining liver derived glucose production in humans with 
dark chocolate consumption are required.    
 
However, the current study did demonstrate a significant treatment difference in glucose Rd 
for both [6, 6-2-H2]glucose and [U-
13C]glucose tracers, with a ~16% reduction in Rd late 
during SS exercise (last 60 min) after DC consumption compared to CON, which was further 
reflected in significantly reduced glucose clearance in the DC treatment (Fig. 4C). The 
corresponding calculated plasma glucose oxidation was ~18% lower during SS exercise after 
DC consumption (Fig. 4A), with a compensatory ~15% increase in muscle glycogen oxidation 
(Fig. 4B).  Taken together, DC consumption altered muscle CHO partitioning, between 
muscle glucose uptake and glycogen oxidation and our data suggests that augmented 
plasma glucose during exercise found with DC was due to an unaltered total glucose Ra and 
a decreased glucose Rd, the combination of which resulted in a subsequent increase in 
plasma glucose concentration and increase in calculated muscle glycogen utilization.  
 
The cocoa liquor found in the DC treatment is rich in (-)-epicatechin and the methylxanthine 
theobromine (240 and 690 mg, respectively) After DC consumption, (-)-epicatechin 
metabolite concentrations peaked at ~700 nM at approximately 2.5 h after consumption (Fig. 
3A&B), which is in agreement with previous studies (Richelle et al. 1999). In contrast, 
circulating theobromine concentrations only reached 70 μM range, which is 100 fold higher 
than that of (-)-epicatechin metabolites.  However, the effect of caffeine after DC 
consumption was negligible because caffeine concentrations remained nearly at the baseline 
levels (Fig 3). The timing of the peak in (-)-epicatechin concentration coincides with both the 
first significant increase in plasma glucose in the DC compared to CON condition as well as 
to exercise onset.  The primary means of skeletal muscle glucose uptake (glucose Rd) is via 
intracellular translocation of the glucose transporter-4 (GLUT4) to the plasma membrane, 
which is mediated via both insulin and exercise/contraction mechanisms (Thorell et al. 1999).  
Intriguingly, several recent in vitro experiments in rodent cell lines have shown a competitive 
inhibition of GLUT4 by some classes of polyphenols (i.e. quercetin, myricetin and catechin-
gallate; (Strobel et al. 2005)), including blocking the insulin-dependent GLUT4 translocation 
by flavanols (Nomura et al. 2008).  However, given that a contraction mediated GLUT4 
translocation mechanisms would have been dominate given our exercise protocol, and that 
we did not quantify GLUT4 from muscle biopsies, the mechanism(s) supporting our finding of 
augmented glucose due to decreased glucose Rd remains elusive.   
  
Theobromine has been shown to be a phosphodiesterase inhibitor and adenosine receptor 
antagonist (Daly et al. 1987). We quantified a very high and similar theobromine 
concentration as found previously after the ingestion of chocolate (Richelle, Tavazzi et al. 
1999), with peak values of nearly 70 μM, sufficient to antagonize the adenosine receptor 
(Fig. 3A).  The only previous study to directly examine the stimulatory and subjective effects 
of pure caffeine compared to theobromine in humans found that a 560 mg dose of 
theobromine did cause significant stimulatory effects compared to a placebo, but less than 
caffeine (Mumford et al. 1994).  Although the mechanistic effects of acute administration of 
theobromine in humans has not been previously studied, several studies have demonstrated 
that the acute increase of other plasma methylxanthine concentrations (e.g. caffeine) have 
consistently been shown to interfere with skeletal muscle plasma glucose uptake both at rest 
and exercise in healthy humans. Acute caffeine ingestion has been shown to decrease leg 
glucose uptake by ~50% (Thong et al. 2002), while theophylline significantly decreased 
glucose Rd during exercise (Raguso, Coggan et al. 1996).  The latter study also found 
significant increases in plasma glucose concurrently with decreased glucose Rd. The effect of 
the methylxanthine theobromine on elevated glucose levels in the DC group might be 
secondary to its adenosine receptor antagonizing activity, as Vergauwen et al. (Vergauwen 
et al. 1994) have previously demonstrated that adenosine receptor antagonists inhibited 
electrical stimulated glucose transport in the presence of insulin in perfused skeletal muscle.  
This supports the present results and previous findings (Davison, Callister et al. 2011) that 
theobromine from DC  increased plasma glucose only after the onset of an exercise stress. 
Similarly, theophylline infusion only decreased glucose Rd during exercise and not at rest 
(Raguso, Coggan et al. 1996).  Recently, Neufingerl et al. reported that theobromine may be 
the main cocoa constituent responsible for the HDL cholesterol raising effect of dark 
chocolate (Neufingerl et al. 2013). Although both theobromine and epicatechins have been 
shown to regulate glucose homeostasis, the 100-fold greater Cmax of theobromine than (-)-
epicatechin metabolites after DC consumption (Fig. 3) makes theobromine a dominate 
candidate for the altered glucose handling found in the present study.   
 
The current study also showed a significant increase in plasma triglycerides in the DC 
treatment vs. CON, which nearly mimicked the plasma kinetic response of measured (-)-
epicatechin (Fig. 2G & Fig. 3B). The high concentrations of plasma triglyceride cannot be 
explained by the amount of triglycerides in the chocolate treatments as both had similar 
amounts of total triglycerides. Yoshikawa et al. (Yoshikawa et al. 2002) reported that (-)-
epicatechin inhibits rat lipoprotein lipase (LPL) activity with the IC50 at 81 mg/L (279 µM). 
Inhibition of LPL activity can prolong the triglyceride clearance in the plasma, which could be 
the mechanism explaining the elevated triglycerides in the DC group. However, whether 
acute DC consumption as found within this study directly has an LPL inhibitory effect remains 
to be determined.  The recent studies by Allgrove et al. (Allgrove, Farrell et al. 2011) and 
Davison et al. (Davison, Callister et al. 2011) both showed significant increases in plasma 
FFA throughout moderate intensity exercise that were greater after dark chocolate 
consumption than control. In contrast, the current study found no differences in FFA 
concentrations during rest or exercise between groups.  
 
Despite differences in plasma glucose between treatments all measured glucose responses 
were euglycemic (>4 mmol), and thus it may not be surprising that the current study found no 
differences in ~11.5 min TT performance, which is consistent with a recent publication 
showing no change in a time to exhaustion performance test over ~6.5 min after chronic and 
acute dark chocolate consumption (Allgrove, Farrell et al. 2011).  Consequently, perhaps a 
more taxing and prolonged exercise stimulus may have altered the performance outcomes.  
A priori there were several reasons to believe that physical performance might be enhanced 
with cocoa-rich DC supplementation. First, during prolonged exercise the maintenance of 
blood glucose levels can delay fatigue and improve performance (Coyle et al. 1983). Since a 
previous study showed an increased maintenance of plasma glucose late during prolonged 
exercise with pre-exercise cocoa-rich dark chocolate consumption, compared to an iso-
carbohydrate control (Davison, Callister et al. 2011), there could be the potential to improve 
performance after prolonged cycling exercise.  Secondly, the methylxanthines, such as 
caffeine, have a long history of enhancing physical and mental performance via primarily 
central nervous system mechanisms (Burke 2008). Interestingly, theobromine has been 
shown to increase time to exhaustion by 38% in rats (Durham et al. 1993).  Despite the fact 
that theobromine is a compound with ~3-fold lower locomotion stimulatory effect than 
caffeine (Snyder et al. 1981), the long half-life (~7 h) and large concentration of theobromine 
in the plasma found in the current study (~70 µM), it could be hypothesized that it may give 
as similar stimulatory effect as ~1 to 2 mg caffeine/kg B.W.  Nevertheless, the acute effect of 
theobromine on exercise or resting metabolism or performance in humans remains to be 
assessed and the 690 mg dose in the DC did not have an impact on the short-duration 
performance test used in this study.   
In summary, through the utilization of glucose-tracer methodologies this is the first study to 
characterize the increases in glycemia and insulinemia during rest, exercise and recovery 
after dark chocolate consumption. This augmented plasma glucose response was not due to 
difference in glucose Ra between treatments.  However, during the later period of SS 
exercise there was a ~16% decrease in Rd, which was reflected in a ~18% decrease in 
plasma glucose oxidation, with a compensatory ~15% increase in muscle glycogen utilization 
(p=0.045) after DC consumption vs. CON during SS exercise.  The molecular mechanisms 
behind our findings remain elusive but either flavanol inhibition of skeletal muscle GLUT4 
translocation and/or methylxanthine adenosine antagonism of glucose uptake may play a 
significant role.  However, these metabolic changes did not impact upon performance.  Given 
the large dietary intakes of both polyphenols and methylxanthines from varying dietary 
sources (Cooper et al. 2008), further scientific examination of their apparent unique bioactive 
metabolic properties, or potential synergies for improving performance is warranted.   
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Figure 2. Glucose, insulin, glucagon & triglycerides concentrations. 














































































































































































































Figure 3.  Plasma theobromine and caffeine (A) and total (-)-epicatechin concentrations (B) 
after DC consumption.     
 
 

























































Figure 4.  Plasma glucose (A) glycogen (B) and glucose clearance (C).   1 
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Figure 1.  Overview of the study protocol.  Resting blood and breath samples were taken 4 
prior to and after either 561 kcal of dark chocolate (DC) or nearly iso-caloric and 5 
carbohydrate low cocoa control chocolate (CON) consumption. Continuous [6,6-2H2]-glucose 6 
and [U-13C]-glucose dual-tracer infusion, breath and blood measurements were made 7 
throughout the end of the rest period and during 2.5h of cycling at 45% VO2peak (steady-state, 8 
SS), time-trial (TT), and recovery periods.   9 
 10 
Figure 2.  Plasma glucose (A&B), insulin (C&D), glucagon (E&F) and triglyceride (G&H) 11 
concentrations and AUC, respectively, at rest, during 2.5h steady-state (SS) cycling at 12 
~45%VO2peak, a ~15min time-trial (TT) and recovery (RECOV) after the consumption of either 13 
561 kcal of dark chocolate (DC) or nearly iso-caloric and carbohydrate low cocoa control 14 
chocolate (CON) 2h prior to exercise. Values are means ± SEM n=16.  † Significant trial 15 
effect of DC different from CON (P<0.05). * DC significantly different from CON at the 16 
corresponding time point (P<0.05). 17 
 18 
Figure 3.  Plasma theobromine and caffeine (A) and total (-)-epicatechin metabolites (B; sum 19 
of aglycone, 3’-O-methyl-epicatechin and 4’-O-methyl-epicatechin) at rest, during 2.5h 20 
steady-state (SS) cycling at ~45%VO2peak and a ~15min time-trial (TT) after the consumption 21 
of 561 kcal of dark chocolate (DC) 2h prior to exercise. Values are means ± SEM n=16.   22 
 23 
Figure 4.  Plasma glucose (A) glycogen (B) and glucose clearance (C) during 2.5h steady-24 
state (SS) cycling at ~45%VO2peak after the consumption of either 561 kcal of dark chocolate 25 
(DC) or nearly iso-caloric and carbohydrate low cocoa control chocolate (CON) 2h prior to 26 
exercise. Values are means ± SEM n=16.  † Significant trial effect: DC different from CON 27 
(P<0.05). * DC significantly different from CON at the corresponding time point (P<0.05).  28 
 29 
 30 
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Body mass index (BMI) is calculated by dividing body mass by height2; SS, 2.5 hr steady-state 43 
cycling period at ~45% VO2peak; TT, ~15min time-trial.   44 
Characteristics n Mean SD Min Max 
Age (Years) 16 30.0 6.1 19 38 
Height (m) 16 179.9 7.8 1.69 1.97 
Weight (Kg) 16 72.8 6.0 65 90 
BMI (Kg/m
2
) 16 22.5 1.4 19.3 24.1 
Cycling per week (hrs) 16 9.4 4.6 4 20 
VO2peak (ml/kg/min) 16 56.3 5.7 45 66 
Cadence (rev/min) 16 89.1 6.1 75 100 
Maximum Wattage (Watts) 16 376.8 27.3 310 418 
SS Power-Output (Watts) 16 142.0 15.9 110 165 
Required Work (kJ) for TT 16 203.6 14.7 168 226 
      
31 
 
Table 2: Overview of the dietary composition for the dark chocolate (DC) and control 45 
chocolate (CON) treatments.  46 
Composition Dark chocolate Control chocolate 
      
Energy (Kcal) 561 544 
Energy (Kjoules) 2329 2251 
   
Fat (g) 43.7 47.9 
Saturates 24.3 27.1 
Mono unsaturates 12.7 13.6 
Polyunsaturates 1.1 1.2 
   
Carbohydrates (g) 33.3 27.5 
Glucose <0.1 <0.1 
Fructose 0.1 <0.1 
Lactose 0.2 <0.1 
Sucrose 27.3 23.4 
Maltose <0.1 <0.1 
   
Cocoa extract (g)   
Fiber 11.4 <0.5 
Protein 8.8 0 
Theobromine  0.69 <0.01 
Caffeine  
 
Cocoa polyphenols (mg)  
0.09 0.01 
Epicatechin 89 <0.05 
Catechin 24 <0.05 
Procyanidin B2 55 <0.05 
Procyanidin B5 15 <0.05 
Trimer C 37 <0.05 




Table 3: Tracer kinetics and calculated tracer substrate source utilization during steady-state 
(SS) cycling at ~45%VO2peak after the consumption of either 561 kcal of dark chocolate (DC) 
or nearly iso-caloric and carbohydrate low cocoa control chocolate (CON) 2h prior to 
exercise.   
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  90.1±3.1 
101.7±4.7 


































Values are expressed as means ± SEM, n=16.  Ra, rate of appearance; Rd, rate of 
disappearance; Rox, rate of oxidation.  † significant trial effect: DC different from CON  






Supplementary Table 1: Cardio-respiratory measures at rest, during 2.5h steady-state (SS) cycling at ~45%VO2peak, a ~15min time-trial (TT) 
and recovery (Recov) after the consumption of either 561 kcal of dark chocolate (DC) or nearly iso-caloric and carbohydrate low cocoa control 
chocolate (CON) 2h prior to exercise.  
 
      Phase     
Parameter Treatment  Rest SS SS SS SS SS Recov Recov 
      Time     
   120 140 160 180 210 240 330 360 

























































































































































Values are expressed as means± SE, n=16, (P<0.05).  VO2, rate of oxygen consumption; VCO2, rate of carbon dioxide expiration; RER, 
respiratory exchange ratio; Oxid., oxidation; HR, heart rate; and RPE, rate perceive exhaustion.  
 
 
